EffRx Pharmaceuticals signs exclusive license agreement with Diurnal for registration and commercialisation of Alkindi

This article was originally published here

Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Alkindi in Switzerland. Alkindi is the first preparation of hydrocortisone specifically designed

The post EffRx Pharmaceuticals signs exclusive license agreement with Diurnal for registration and commercialisation of Alkindi appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply